Prime-Boost Strategies in DNA Vaccines

Dale, C. Jane; Thomson, Scott; Rose, Robert De; Ranasinghe, Charani; Medveczky, C. Jill; Pamungkas, Joko; Boyle, David B.; Ramshaw, Ian A.; Kent, Stephen J.

doi:10.1385/1-59745-168-1:171

Cited by 27 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Different forms of heterologous prime-boost vaccines delivered systemically are currently being tested in a number of ongoing preclinical and clinical trials and hold significant promise for eliciting cellular responses and determining the efficacy of T-cell based vaccines (Allen et al, 2000; Amara et al, 2001; Barouch et al, 2000; Belshe et al, 1998; Dale et al, 2006; Gherardi et al, 2003; Hel et al, 2001b; Kent et al, 1998; Neeson et al, 2006; O'Neill et al, 2002; Sharpe et al, 2003; Tritel et al, 2003; Wierzbicki et al, 2002; Wille-Reece et al, 2006). Heterologous prime-boost immunization is a proven strategy that elicits high frequencies of effector and memory T cells, and in particular high-avidity CD8 + CTL that are relevant to vaccine efficacy (Alexander-Miller et al, 1996; Belyakov et al, 2007a, 2007b, 2006b; Derby et al, 2001; Estcourt et al, 2002; Gallimore et al, 1998; Masopust et al, 2006; Ranasinghe et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization

Belyakov

Ahlers²,

Nabel

et al. 2008

Virology

View full text Add to dashboard Cite

Gastrointestinal and vaginal mucosa are major sites of entry in natural HIV infection and therefore the preferred sites to elicit high-avidity CD8+ CTL by vaccination. We directly compare systemic and mucosal immunization in mice after DNA priming and boosting with rgp160 env expressed either in MVA or Ad for their ability to induce mucosal as well as systemic HIV-specific CTL. The optimal CTL response in the gut mucosa was observed after priming with the HIV-1 gp160 env DNA vaccine and boosting with rMVA or rAd encoding the same envelope gene all administered intrarectally (IR). Maximum levels of high-avidity CD8+ T cells were seen in intestinal lamina propria following this regimen. When the prime and boost routes were distinct, the delivery site of the boost had a greater impact than the DNA priming. IM DNA prime and IR rMVA boost were more effective than IR DNA prime and IM rMVA boost for eliciting mucosal CD8+ T-cell avidity. A systemic DNA-prime-followed by systemic rMVA boost induced high levels of high-avidity CD8+ T cells systemically, but responses were undetectable in mucosal sites. A single systemic immunization with rMVA was sufficient to induce high-avidity IFN-γ secreting CD8+ T cells in systemic organs, whereas a single mucosal immunization with rMVA was not sufficient to elicit high-avidity CD8+ T cells in mucosa. Thus, a heterologous mucosal DNA prime-viral vectored boost strategy was needed. The requirement for a heterologous DNA prime-recombinant viral boost strategy for generation of high-avidity CD8+ T cells in mucosal sites in mice may be more stringent than for the induction of high-avidity CD8+ T cells in systemic compartments.

show abstract

Section: Introductionmentioning

confidence: 99%

Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization

Belyakov

Ahlers²,

Nabel

et al. 2008

Virology

View full text Add to dashboard Cite

show abstract

“…intra-muscularly, intra-peritoneally, intra-venously and intra-splenicly) it was observed that only the intra-splenic route was the most efficient at inducing specific antibody production after a single injection of DNA. Although it has been verified that a single intra-muscular immunisation with plasmid DNA was sufficient for antibody response (Bohm et al 1996), in other reports at least two DNA injections were required (Davis 1997;Dale et al 2006). These results were supported also by Kasinrerk et al (2002) who demonstrated that only the intra-splenic route could induce a specific antibody response after a single DNA injection.…”

Section: Genetic Immunisation and Delivery Routementioning

confidence: 88%

Mouse monoclonal antibodies in biological research: strategies for high-throughput production

Chiarella

Fazio

2008

Biotechnol Lett

View full text Add to dashboard Cite

Mouse monoclonal antibodies have become key components in basic research as well as in the clinical laboratory. Being invaluable tools in many biological assays, they continue to be the primary choice in the research field, although the conventional technology used for hybridoma generation and screening is a still lengthy, time-consuming and low-throughput process. With the advent of genetic immunisation and the application of automation and microarray to the traditional biological assays, the monoclonal antibody field has been revolutionised. Here, we will briefly review the most relevant strategies which have made the manufacture of murine monoclonal antibodies a faster and high-throughput technology.

show abstract

“…We can not obviously make general predictions based on the immune responses of mice, and the potential of using pVAX1/P48 immunization for the control of contagious agalactia will be evaluated in sheep. The immunization (and challenge) of sheep will take into account the enhancement of humoral immunity through the prime-boost strategy (Dale et al, 2006), that is, priming with pVAX1/P48 and boosting with rP48.…”

Section: Discussionmentioning

confidence: 99%

Genetic immunization with the immunodominant antigen P48 of Mycoplasma agalactiae stimulates a mixed adaptive immune response in BALBc mice

Chessa

Pittau

Puricelli

et al. 2009

Research in Veterinary Science

View full text Add to dashboard Cite

a b s t r a c tA DNA vaccine against contagious agalactia was developed for the first time, encoding the P48 of Mycoplasma agalactiae. Specific immune responses elicited in BALB/c mice were evaluated. Both total IgG and IgG1 were detected in mice vaccinated with pVAX1/P48. Proliferation of mononuclear cells of the spleen, levels of gamma interferon, interleukin-12, and interleukin-2 mRNAs were enhanced in immunized animals. Results indicate that pVAX1/P48 vaccination induced both T h 1 and T h 2 immune responses. Nucleic acid immunization could be a new strategy against M. agalactiae infections and may be potentially used to develop vaccines for other Mycoplasma diseases.

show abstract

Prime-Boost Strategies in DNA Vaccines

Cited by 27 publications

References 34 publications

Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization

Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization

Mouse monoclonal antibodies in biological research: strategies for high-throughput production

Genetic immunization with the immunodominant antigen P48 of Mycoplasma agalactiae stimulates a mixed adaptive immune response in BALBc mice

Contact Info

Product

Resources

About